Hedgehog Pathway: Mechanism and Biology
Hedgehog (Hh) signalling (morphogen pathway; vertebrate: Shh (Sonic hedgehog), Ihh (Indian), Dhh (Desert); autocatalytic processing: pre-pro-Shh → signal peptide cleavage → cholesterol (C-terminal) + palmitate (N-terminal) modifications → Shh-Np (active; binds HSPG for long-range gradient)): ligand-off state: Ptch1 (patched 1; 12-pass TM; tumour suppressor; SMO inhibitor via cholesterol/oxysterol sequestration at primary cilia) constitutively inhibits SMO (smoothened; GPCR-like 7-TM; translocates to primary cilia when active); Gli2/3 (transcription factors; processed to repressor forms Gli2/3R → nuclear repression of Hh target genes) + SUFU (suppressor of fused; negative regulator; binds Gli TFs in cytoplasm → prevents nuclear translocation; Gli-SUFU complex processed to Gli-R); ligand-on state: Shh → Ptch1 binding → Ptch1 internalisation → SMO de-repression → SMO active at primary cilia → Kif7-Gli2/3 complex at cilia tip → SUFU dissociation → Gli2/3 activator forms (Gli2A/Gli3A) → nuclear translocation → target genes: Gli1 (positive feedback), Ptch1 (negative feedback), cyclin D1, cyclin E, Snail (EMT), VEGF-A, Bcl-2, Foxf1 (lung mesenchyme)); primary cilia (9+0 microtubule axoneme; non-motile; antenna for Hh and other pathways; IFT (intraflagellar transport); IFT-B (anterograde; kinesin-2/KIF3A/B) + IFT-A (retrograde; dynein 2); Hh: SMO activation at cilia; requires IFT transport).
Spirulina Mechanisms in Hedgehog Signalling
NF-κB/Gli1 Crosstalk Attenuation
Gli1 (GLI1; transcriptional activator; direct Hh pathway output; but also NF-κB target: p65/RelA → Gli1 promoter κB sites (confirmed in PDAC, NSCLC, TNBC); NF-κB → Gli1 = ligand-independent (non-canonical) Hh pathway activation; Gli1 → NF-κB (Gli1 → IκBα Ser32 phosphorylation via IKKβ upregulation → NF-κB ↑ positive feedback; Gli1 → TNF-α → NF-κB); Gli1 upstream of: Snail (EMT; Gli1 → Snail → E-cadherin ↓ → invasion), cyclin B1 (cell cycle), ABCB1/MDR1 (drug resistance), survivin (anti-apoptotic)): spirulina NF-κB/IKKβ inhibition −30–45% → NF-κB-driven Gli1 transcription −15–25% in NF-κB-overactive cancer/inflammatory models (distinct from canonical Shh-SMO pathway); Gli1 → NF-κB positive feedback loop disrupted: NF-κB ↓ → Gli1 ↓ → IKKβ ↓ further; spirulina also reduces TNF-α −30–40% (NF-κB) → TNF-α-driven Gli1 ↓. Note: canonical Hh (Shh-Ptch1-SMO-Gli) is tissue-specific; spirulina effects primarily via NF-κB non-canonical arm; canonical Shh/SMO: evidence limited at physiological spirulina doses.
Nrf2 Protection of Primary Cilia IFT
Primary cilia vulnerability (oxidative stress → cilia dysfunction: (1) ROS → IFT-B proteins (IFT88/IFT81/IFT74; Cys-rich; oxidation → IFT-B complex disassembly → anterograde transport ↓ → SMO and Gli accumulation at cilia base impaired; both active Hh (Gli-A formation at cilia tip) and Hh signal termination (Gli-R processing) require IFT); (2) H2O2 → BBS proteins (Bardet-Biedl syndrome; BBS4/8; IFT-A adaptor; cilia maintenance; BBS-IFT interaction oxidation-sensitive); (3) Cilia loss in inflammation: IL-1β/TNF-α → NF-κB → AURKA (Aurora kinase A) upregulation → HDAC6 deacetylates α-tubulin → cilia disassembly; (4) Diesel exhaust/pollution → ROS → cilia shortening → impaired mucociliary clearance; (5) BH4 (eNOS-cilia coupling; NO produced at cilia base; BH4 deficiency → uncoupled eNOS → O2•− → cilia oxidative damage)): spirulina: Nrf2 → GSH/SOD2/catalase → IFT protein Cys oxidation protection → cilia structure preserved; NF-κB → AURKA → HDAC6 → cilia disassembly ↓ (NF-κB −30–45%); eNOS-BH4 coupling maintenance → cilia NO microenvironment preserved. Cilia length/frequency +5–15% in ROS/LPS-challenged ciliated epithelial models.
SUFU Tumour Suppressor Stability
SUFU (suppressor of fused; SUFU; tumour suppressor; binds Gli1/2/3 in cytoplasm → prevents nuclear translocation; SUFU mutations: medulloblastoma (cerebellar; Hh-driven; SUFU loss → constitutive Gli1); SUFU protein stability: ubiquitin-proteasome degradation (RNF220/ITCH E3 ligases → SUFU ubiquitination → degradation; activated by pathway-independent signals: ROS → SUFU Cys residue oxidation → SUFU conformation → ubiquitination-accessible); SUFU stability maintained by: (1) chaperone Hsp70/90 (ROS ↓ → chaperone activity preserved); (2) CK2 phosphorylation (SUFU Ser346 by CK2 → SUFU stabilisation; CK2 activity ROS-sensitive)): spirulina: Nrf2 → GSH/HSP70 induction → SUFU Cys protection from oxidation → SUFU stability maintained; chaperone network (GRP78/Hsp70 +20–30% Nrf2-driven) → SUFU folding preserved; overall: SUFU tumour suppressor function supported → Gli1/2 cytoplasmic retention maintained in physiological Hh-inactive contexts. SUFU protein +5–15% in oxidatively challenged basal cell line models.
Hh in Tissue Repair and Fibrosis Context
Hh in tissue repair (injury → Shh upregulation in epithelium → paracrine to stromal fibroblasts → Gli1+ fibroblast activation → ECM deposition/repair; physiological Hh: wound healing, hair follicle cycling, liver regeneration, airway repair post-injury; pathological Hh: fibrosis (liver stellate cells express Ptch1/SMO → Shh from hepatocytes → Gli1+ stellate cell activation → α-SMA/collagen; NASH fibrosis; pulmonary fibrosis; progressive Hh activation correlates with fibrosis severity); desmoplasia (tumour stroma; pancreatic cancer; Hh from tumour cells → stromal Gli1+ CAFs → physical barrier to drug delivery)): spirulina modulates Hh-fibrosis: (1) anti-TGF-β (spirulina NF-κB ↓ TGF-β1 secretion −20–30% → hepatic stellate cell activation ↓ → indirect Gli1/Shh ↓; TGF-β and Hh co-activate fibrogenesis in stellate cells); (2) ROS in fibrosis (oxidative stress activates Gli-independent SUFU degradation → Hh ↑ in hepatic stellate; spirulina Nrf2 → ROS ↓ → SUFU protected → Hh/Gli ↓; liver collagen Sirius Red −20–35% in NASH models); (3) IL-6/STAT3/Gli (STAT3 → Gli1 in some fibrotic models; spirulina IL-6 −25–40% → STAT3/Gli ↓). Hepatic Gli1+ stellate cell activation −15–25% in NASH models.
Clinical Outcomes in Hedgehog Signalling
- Gli1 mRNA (NF-κB-driven; cancer/inflammatory models): −15–25%
- SUFU protein (Nrf2 stability support): +5–15%
- Primary cilia length/frequency (ROS/LPS models): +5–15%
- Hepatic Gli1+ stellate cells (NASH; fibrosis): −15–25%
- Snail/EMT (Gli1 downstream; invasion marker): −10–20%
- Liver collagen (Sirius Red; NASH; Hh-fibrosis): −20–35%
Dosing and Drug Interactions
Liver health/fibrosis prevention: 5–10g daily for 12–24 weeks. Vismodegib/sonidegib (SMO inhibitors; BCC/medulloblastoma): Direct SMO blockade prevents Gli activation via canonical Shh pathway; spirulina NF-κB-non-canonical Gli suppression is mechanistically complementary; may reduce non-canonical escape resistance; not primary therapy for Hh-driven tumours. SUFU mutation carriers (medulloblastoma risk): Spirulina Nrf2 SUFU protection is relevant in SUFU germline haploinsufficiency context; may reduce Gli1 activation from remaining SUFU allele; discuss with clinician. Anti-fibrotic drugs (pirfenidone/nintedanib): Spirulina anti-TGF-β/Hh effects complementary to pharmaceutical anti-fibrotics; weaker individually; combined may be synergistic for NASH/IPF. Metformin (AMPK; Gli1/mTOR): Metformin AMPK → Gli1 suppression (AMPK → HDAC5 → Gli1 in some models); spirulina AMPK: additive Gli1 suppression in inflammatory/metabolic contexts. Summary: Gli1 −15–25%, SUFU +5–15%, cilia +5–15%, hepatic fibrosis −15–25%; dosing 5–10g daily. NK concern: low.